1. Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58
2. Shepherd J, Barter P, Carmena R et al. Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes. The Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220–6.
3. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–96.
4. Schulz R. Pleiotropic effects of statins: acutely good, but chronically bad? J Am Coll Cardiol 2005; 45: 1292–4.
5. Sanguigni V, Pignatelli P, Lenti L et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005; 111: 412–9.
6. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115–26.
7. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol 2003; 91 (Suppl.): 4B–8B.
8. Pasceri V, Patti G, Nusca A et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110 (6): 674–8.
9. Patti G, Pasceri V, Colonna G et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the 
ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49 (12): 1272–8.
10. Di Sciascio G, Patti G, Pasceri V et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatinfor Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009; 54 (6): 558–65.
11. Kim JS, Kim J, Choi D et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATINSTEMI trial. JACC Cardiovasc Int 2010; 3 (3): 332–9.
12. Briguori C, Visconti G, Focaccio A et al. Novel Approaches for Preventing or Limiting Events (Naples) II Trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009; 54: 2157–63.
13. Patti G, Cannon CP, Murphy SA et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 2011; 123: 1622–32.
14.  Furie KL, Kasner SE, Adams RJ et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42 (1): 227–76.
15. Writing Group Members, Roger VL, Go AS et al. Heart disease and stroke statistics – 2012 update. Circulation 2012; 125: e2–e220.
16. De Weerd M, Greving JP, De Jong AW et al. Prevalence of asymptomatic carotid artery stenosis according to age and sex: systematic review and metaregression analysis Stroke. J Cereb Circul 2009; 40: 1105–13.
17. Sander DDC, Eckstein HH et al. S3 Guideline Extracranial Carotid Stenosis, chapter 6: Epidemiology. Gefässchirurgie 2012; 17: 497–501.
18. Nicolaides AN, Kakkos SK, Griffin M et al. Severity of asymptomatic carotid stenosis and risk of ipsilateral hemispheric ischaemic events: results from the ACSRS study European Journal of Vascular and Endovascular Surgery. Official J Eur Soc Vasc Surg 2005; 30: 275–84.
19. Stein JH, Korcarz CE, Hurst RT et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: A consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. J Am Soc Echocardiogr 2008; 21: 93–111.
20. Nighoghossian N, Derex L, Douek P. The vulnerable carotid artery plaque: current imaging methods and new perspectives. Stroke 2005; 36: 2764–72.
21. Brott TG, Halperin JL, Abbara S et al. АSA/ACCF/AHA/AANN/ AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the management of patients with extracranial carotid and vertebral artery disease. J Am Coll Cardiol 2011; 57: 1002–44.
22. Tendera M, Aboyans V, Bartelink ML et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2851–906.
23. Ricotta JJ, Aburahma A, Ascher E et al. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. J Vasc Surg 2011; 54: e1–e31.
24. Negre-Aminou P, Van Vliet AK, Van Erck M et al. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997; 1345 (3): 259–68.
25. Hinoi T, Matsuo S, Tadehara F et al. Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography. Am J Cardiol 2005; 96: 89–91.
26. Wassmann S, Faul A, Hennen B et al. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. Circ Res 2003; 93: e98–e103.
27. Laufs U, Wassmann S, Hilgers S et al. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001; 88 (11): 1306–7.
28. Tannous M, Cheung R, Vignini A, Mutus B. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost 1999; 82 (5): 1390–4.
29. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis. A Randomized Controlled Trial. JAMA 2004; 291: 1071–80.
30. Bonnet J, McPherson R, Tedgui A et al. Comparative effects of 
10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther 2008; 30 (12): 2298–313.
31. Ridker PM, Cannon CP, Morrow D et al. For PROVE IT-TIMI22 Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352 (1): 20–8.
32. Wilson PWF, Pencina M, Jacques P et al. C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008; 1: 92–7.
33. Shiomi M, Ito T, Hirouchi Y, Enomoto M. Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins. Atherosclerosis 2001; 157: 75–84.
34. Martin-Ventura JL, Blanco-Colio LM, Gomez-Hernandez A et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 2005; 36: 1796–800.
35. Tang TY, Howarth SP, Miller SR et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009; 53 (22): 2039–50.
36. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1995; 325: 445–53.
37. Michael D, Walker MD, John R et al. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. J Am Med Assoc 1995; 273: 1421–8.
38. Mas JL, Chatellier G, Beyssen B et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. 
N Engl J Med 2006; 355: 1660–71.
39. Eckstein HH, Ringleb P, Allenberg JR et al. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol 2008; 7 (10): 893–902.
40. Gurm HS, Yadav JS, Fayad P et al. SAPPHIRE Investigators, Long-term results of carotid stenting vs endarterectomy in high-risk patients. N Engl J Med 2008; 358 (15): 1572–9.
41. Mantese VA, Timaran CH, Chiu D et al. CREST Investigators The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST): stentingversus carotid endarterectomy for carotid disease. Stroke 2010; 41 (Suppl. 10): S31–4.
42.Gröschel K, Ernemann U, Schulz JB et al. Statin therapy at carotid angioplasty and stent placement: effect on procedure-related stroke, myocardial infarction, and death. Radiology 2006; 240: 145–51.
43. Patti G, Tomai F, Melfi R et al. Strategies of Clopidogrel Load and Atorvastatin Reload to Prevent Ischemic Cerebral Events in Patients Undergoing Protected Carotid Stenting: Results of the Randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting) Study. J Am Coll Cardiol 2013; 61 (13): 1379–87.
44. Ifergan I, Wosik K, Cayrol R et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol 2006; 60: 45–55.
45. Yang D, Knight RA, Han Y et al. Vascular recovery promoted by atorvastatin and simvastatin after experimental intracerebral hemorrhage: magnetic resonance imaging and histological study. 
J Neurosurg 2011; 114: 1135–42.
46. Jung KH, Chu K, Jeong SW et al. HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke 2004; 35: 1744–9.
47. Endres M, Laufs U, Huang Z et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95: 8880–5.

А.В.Руденко1, Б.А.Руденко2

1. ФГБУ Российский кардиологический научно-производственный комплекс Минздрава России, Москва;
2. ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава России, Москва